作者: Georgia Kourlaba , Vassilis Fragoulakis , Nikos Maniadakis
DOI: 10.2165/11633820-000000000-00000
关键词: Aspirin 、 Clopidogrel 、 Myocardial infarction 、 Medicine 、 ST segment 、 Unstable angina 、 Cardiology 、 Acute coronary syndrome 、 Prasugrel 、 Internal medicine 、 Angina
摘要: Background: Current guidelines recommend treatment with antiplatelet and anticoagulant therapy for the secondary prevention of atherothrombotic events among patients non-ST-segment elevation myocardial infarction (NSTEMI) or unstable angina (UA). The CURE (Clopidogrel in Unstable to prevent Recurrent Events) trial has shown that clopidogrel alone combination aspirin is more effective reducing risk than NSTEMI UA patients. However, current climate financial constraints, effectiveness a should be considered conjunction its long-term economic costs determine best possible care.